Cancers · 2021 · 18 citations · 26 references
MedicineGeneticsOncologyCancer GeneticsChemotherapyMolecular OncologyCancer GenomicsCancer PharmacogenomicsCancer ProgressionLung CancerMalignant NeoplasmsTyrosine Kinase InhibitorsEgfr InhibitionEgfr Mutation TestingNon-small Cell Lung Cancer TherapyNon-small Cell Lung Cancer TreatmentProgressive Disease AssessmentProgressive Disease QuantificationRare Genetic VariantsTumor Response Evaluation
EGFR exon 20 insertions are rare genetic alterations in non-small-cell lung cancers (NSCLCs) that are usually unresponsive to approved EGFR tyrosine kinase inhibitors (TKIs). In this paper, we describe the clinical characteristics, efficacy of EFGR TKIs and chemotherapy, and resulting survival in this population. We retrospectively collected patients with EGFR exon 20 insertions (Exon20ins) from 11 French genetic platforms and paired them (1:2 ratio) with classic Exon 19/21 EGFR mutation patients (controls). Between 2012 and 2017, 35 Exon20ins patients were included. These patients were younger at diagnosis than the controls. All Exon20ins patients who were treated with first-line EGFR TKIs (n = 6) showed progressive disease as the best tumor response. There was no significant difference in the tumor response or the disease control rate with first-line platinum-based chemotherapy between the two groups. A trend towards shorter overall survival was observed in Exon20ins vs. controls (17 months (14—not reach(NR) 95% confidence interval(CI) vs. 29 months (17–NR 95%CI), p = 0.09), respectively. A significant heterogeneity in amino acid insertion in EGFR exon 20 was observed. EGFR exon 20 insertions are heterogeneous molecular alterations in NSCLC that are resistant to classic EGFR TKIs, which contraindicates their use as a first-line treatment.
26
Ethan Cerami, Jianjiong Gao, Uğur Doğrusöz et al. · Cancer Discovery · 2012 · 18.4K citations · Full text
Medicine, Bioinformatics, Oncology +15
Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal
Jianjiong Gao, Bülent Arman Aksoy, Uğur Doğrusöz et al. · Science Signaling · 2013 · 15.9K citations · Full text
Medicine, Bioinformatics, Oncology +17
Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
Tony Mok, Yi‐Long Wu, Sumitra Thongprasert et al. · New England Journal of Medicine · 2009 · 8.2K citations · Full text
Medicine, Oncology, Pharmacology +13
Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR
Makoto Maemondo, Akira Inoue, Kunihiko Kobayashi et al. · New England Journal of Medicine · 2010 · 5.6K citations
Medicine, Oncology, Pharmacology +13
Rafael Rosell, Enric Carcereny, Radj Gervais et al. · The Lancet Oncology · 2012 · 5.5K citations · Full text
Medicine, Oncology, Pharmacology +12